抗惊厥药佐尼沙胺可减少风险饮酒者的乙醇自我给药。

The anticonvulsant zonisamide reduces ethanol self-administration by risky drinkers.

机构信息

Boston University School of Medicine, Massachusetts, USA.

出版信息

Am J Drug Alcohol Abuse. 2009;35(5):316-9. doi: 10.1080/00952990903060150.

DOI:10.1080/00952990903060150

PMID:19637104

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4028067/

Abstract

OBJECTIVE

The purpose of this study is to examine the effects of zonisamide on ethanol self-administration and subjective effects in risky drinkers using a human laboratory paradigm.

METHOD

We conducted a double-blind, placebo-controlled study of the effects of zonisamide 100 mg on ethanol self-administration and urge to drink in risky drinkers (N = 10) ( [1] ).

RESULT

During the second hour of a 2-hour self-administration session ethanol consumption was 50% lower in the zonisamide group as compared to the placebo group. Urge to drink was also significantly lower under the zonisamide condition.

CONCLUSION

These results indicate that a single dose of zonisamide reduces urge to drink and the quantity of ethanol self-administered by risky drinkers during their second hour of access to alcohol.

SCIENTIFIC SIGNIFICANCE

Zonisamide may help individuals drinking at risky levels reduce their intake of alcohol.

摘要

目的

本研究旨在通过人类实验室范式，考察唑尼沙胺对风险饮酒者乙醇自我给药和主观效应的影响。

方法

我们进行了一项双盲、安慰剂对照研究，评估了 100 毫克唑尼沙胺对风险饮酒者（N=10）（[1]）乙醇自我给药和饮酒欲望的影响。

结果

在 2 小时自我给药期间，与安慰剂组相比，唑尼沙胺组的乙醇摄入量降低了 50%。在唑尼沙胺组，饮酒欲望也明显降低。

结论

这些结果表明，单次服用唑尼沙胺可减少风险饮酒者在接触酒精的第二个小时内的饮酒欲望和乙醇自我给药量。

科学意义

唑尼沙胺可能有助于饮酒量处于风险水平的个体减少酒精摄入量。

相似文献

The anticonvulsant zonisamide reduces ethanol self-administration by risky drinkers.

Am J Drug Alcohol Abuse. 2009;35(5):316-9. doi: 10.1080/00952990903060150.

Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders.

J Clin Psychopharmacol. 2015 Feb;35(1):34-42. doi: 10.1097/JCP.0000000000000246.

Placebo-controlled trial of zonisamide for the treatment of alcohol dependence.

J Clin Psychopharmacol. 2010 Jun;30(3):318-22. doi: 10.1097/JCP.0b013e3181db38bb.

Zonisamide decreases ethanol intake in rats and mice.

Pharmacol Biochem Behav. 2007 May;87(1):65-72. doi: 10.1016/j.pbb.2007.04.001. Epub 2007 Apr 11.

Differentiating the contribution of pharmacological from alcohol expectancy effects to changes in subjective response and priming over successive drinks.

Alcohol Clin Exp Res. 2013 Apr;37(4):687-95. doi: 10.1111/acer.12022. Epub 2012 Oct 17.

The Impact of Zonisamide on the Development and Course of Alcohol Dependence in Rabbits. A pharmaco-EEG study.

Alcohol Alcohol. 2017 May 1;52(3):282-288. doi: 10.1093/alcalc/agx003.

Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study.

Alcohol Clin Exp Res. 2008 Mar;32(3):489-97. doi: 10.1111/j.1530-0277.2007.00592.x. Epub 2008 Jan 22.

Zonisamide for weight loss in obese adults: a randomized controlled trial.

JAMA. 2003 Apr 9;289(14):1820-5. doi: 10.1001/jama.289.14.1820.

Effects of Varenicline on Neural Correlates of Alcohol Salience in Heavy Drinkers.

Int J Neuropsychopharmacol. 2015 Jul 25;18(12):pyv068. doi: 10.1093/ijnp/pyv068.

Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial.

Clin Drug Investig. 2011;31(4):221-9. doi: 10.2165/11539750-000000000-00000.

引用本文的文献

Zonisamide Ameliorated the Apoptosis and Inflammation in Cerebellar Tissue of Induced Alcohol Addiction Animal Model.

Life (Basel). 2024 Jun 24;14(7):795. doi: 10.3390/life14070795.

A Review of the Characteristics of Clinical Trials and Potential Medications for Alcohol Dependence: Data Analysis from ClinicalTrials.gov.

Medicina (Kaunas). 2023 Jun 7;59(6):1101. doi: 10.3390/medicina59061101.

A Novel Sulfonamide, 4-FS, Reduces Ethanol Drinking and Physical Withdrawal Associated With Ethanol Dependence.

Int J Mol Sci. 2020 Jun 21;21(12):4411. doi: 10.3390/ijms21124411.

Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review.

Alcohol Clin Exp Res. 2019 Apr;43(4):550-563. doi: 10.1111/acer.13964. Epub 2019 Feb 19.

State-of-the-art behavioral and pharmacological treatments for alcohol use disorder.

Am J Drug Alcohol Abuse. 2019;45(2):124-140. doi: 10.1080/00952990.2018.1528265. Epub 2018 Oct 29.

Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Addict Biol. 2017 May;22(3):581-615. doi: 10.1111/adb.12349. Epub 2016 Feb 1.

Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders.

CNS Drugs. 2015 Apr;29(4):293-311. doi: 10.1007/s40263-015-0240-4.

Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders.

J Clin Psychopharmacol. 2015 Feb;35(1):34-42. doi: 10.1097/JCP.0000000000000246.

PTSD and comorbid AUD: a review of pharmacological and alternative treatment options.

Subst Abuse Rehabil. 2014 Mar 7;5:25-36. doi: 10.2147/SAR.S37399. eCollection 2014.

Voluntary intravenous self-administration of alcohol detects an interaction between GABAergic manipulation and GABRG1 polymorphism genotype: a pilot study.

Alcohol Clin Exp Res. 2013 Jan;37 Suppl 1(0 1):E152-60. doi: 10.1111/j.1530-0277.2012.01885.x. Epub 2012 Jul 20.

本文引用的文献

Topiramate for treating alcohol dependence: a randomized controlled trial.

JAMA. 2007 Oct 10;298(14):1641-51. doi: 10.1001/jama.298.14.1641.

Zonisamide decreases ethanol intake in rats and mice.

Pharmacol Biochem Behav. 2007 May;87(1):65-72. doi: 10.1016/j.pbb.2007.04.001. Epub 2007 Apr 11.

Activation by zonisamide, a newer antiepileptic drug, of large-conductance calcium-activated potassium channel in differentiated hippocampal neuron-derived H19-7 cells.

J Pharmacol Exp Ther. 2007 Apr;321(1):98-106. doi: 10.1124/jpet.106.116954. Epub 2007 Jan 25.

Zonisamide at clinically relevant concentrations inhibits field EPSP but not presynaptic fiber volley in rat frontal cortex.

Epilepsy Res. 2005 Oct-Nov;67(1-2):51-60. doi: 10.1016/j.eplepsyres.2005.08.006. Epub 2005 Sep 26.

Zonisamide: chemistry, mechanism of action, and pharmacokinetics.

Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. doi: 10.1016/j.seizure.2004.04.016.

Ionotropic glutamate receptor antagonists modulate cue-induced reinstatement of ethanol-seeking behavior.

Alcohol Clin Exp Res. 2004 Apr;28(4):558-65. doi: 10.1097/01.alc.0000122101.13164.21.

Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons.

J Neurosci. 2003 Aug 6;23(18):7069-74. doi: 10.1523/JNEUROSCI.23-18-07069.2003.

Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.

Psychopharmacology (Berl). 2002 Feb;160(1):19-29. doi: 10.1007/s002130100919. Epub 2002 Jan 22.

Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance.

Neuropharmacology. 2002 Feb;42(2):210-20. doi: 10.1016/s0028-3908(01)00171-x.

Effects of zonisamide on dopaminergic system.

Epilepsy Res. 1995 Nov;22(3):193-205. doi: 10.1016/0920-1211(95)00078-x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

抗惊厥药佐尼沙胺可减少风险饮酒者的乙醇自我给药。

The anticonvulsant zonisamide reduces ethanol self-administration by risky drinkers.

机构信息

Boston University School of Medicine, Massachusetts, USA.

出版信息

Am J Drug Alcohol Abuse. 2009;35(5):316-9. doi: 10.1080/00952990903060150.

DOI:10.1080/00952990903060150

PMID:19637104

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4028067/

Abstract

OBJECTIVE

The purpose of this study is to examine the effects of zonisamide on ethanol self-administration and subjective effects in risky drinkers using a human laboratory paradigm.

METHOD

We conducted a double-blind, placebo-controlled study of the effects of zonisamide 100 mg on ethanol self-administration and urge to drink in risky drinkers (N = 10) ( [1] ).

RESULT

CONCLUSION

These results indicate that a single dose of zonisamide reduces urge to drink and the quantity of ethanol self-administered by risky drinkers during their second hour of access to alcohol.

SCIENTIFIC SIGNIFICANCE

Zonisamide may help individuals drinking at risky levels reduce their intake of alcohol.

摘要

目的

本研究旨在通过人类实验室范式，考察唑尼沙胺对风险饮酒者乙醇自我给药和主观效应的影响。

方法

我们进行了一项双盲、安慰剂对照研究，评估了 100 毫克唑尼沙胺对风险饮酒者（N=10）（[1]）乙醇自我给药和饮酒欲望的影响。

结果

在 2 小时自我给药期间，与安慰剂组相比，唑尼沙胺组的乙醇摄入量降低了 50%。在唑尼沙胺组，饮酒欲望也明显降低。

结论

这些结果表明，单次服用唑尼沙胺可减少风险饮酒者在接触酒精的第二个小时内的饮酒欲望和乙醇自我给药量。

科学意义

唑尼沙胺可能有助于饮酒量处于风险水平的个体减少酒精摄入量。

抗惊厥药佐尼沙胺可减少风险饮酒者的乙醇自我给药。

The anticonvulsant zonisamide reduces ethanol self-administration by risky drinkers.

机构信息

出版信息

OBJECTIVE

METHOD

RESULT

CONCLUSION

SCIENTIFIC SIGNIFICANCE

目的

方法

结果

结论

科学意义

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

抗惊厥药佐尼沙胺可减少风险饮酒者的乙醇自我给药。

The anticonvulsant zonisamide reduces ethanol self-administration by risky drinkers.

机构信息

出版信息

OBJECTIVE

METHOD

RESULT

CONCLUSION

SCIENTIFIC SIGNIFICANCE

目的

方法

结果

结论

科学意义